SCHEMBL442294

SCHEMBL442294

Nc1nc2c(ncn2[C@H]2C[C@H](O)[C@@H](COO)O2)c(=O)[nH]1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.71
P2RY2 P41231 1/20 0.59
P2RY4 P51582 1/20 0.59
P2RY6 Q15077 1/20 0.59
TYMP P19971 1/20 0.53
NT5E P21589 2/20 0.51
HINT1 P49773 1/20 0.51
PDE3A Q14432 2/20 0.50
PNP P00491 1/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.50
PDE4D Q08499 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
POLA1 P09884 1/20 0.48
GSK3A P49840 2/20 0.48
RPS6KA3 P51812 2/20 0.48
MAPK14 Q16539 2/20 0.48
STING1 Q86WV6 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8490891 0.92 POLB (0.71) POLBP2RY2P2RY4P2RY6TYMP
SCHEMBL15798769 0.91 POLB (0.70) POLBP2RY2P2RY4P2RY6TYMP
SCHEMBL16359949 0.91 POLB (0.70) POLBP2RY2P2RY4P2RY6TYMP
SCHEMBL15012843 0.91 POLB (0.70) POLBP2RY2P2RY4P2RY6TYMP
SCHEMBL338650 0.91 POLB (0.70) POLBP2RY2P2RY4P2RY6TYMP
SCHEMBL20266299 0.90 POLB (0.72) POLBP2RY2P2RY4P2RY6TYMP
SCHEMBL25171429 0.89 POLB (0.82) POLBP2RY2P2RY4P2RY6NT5E
SCHEMBL3744960 0.89 POLB (0.68) POLBP2RY2P2RY4P2RY6TYMP
SCHEMBL48232 0.89 POLB (0.82) POLBP2RY2P2RY4P2RY6NT5E
SCHEMBL22054664 0.89 POLB (0.68) POLBP2RY2P2RY4P2RY6TYMP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020197905-A1 USE OF INOSINE FOR CANCER IMMUNOTHERAPY IMMUNOSPARKLE BIOSCIENCE LLC (US) 2020-10-01 WO claimed
US-10736913-B1 Use of inosine for cancer immunotherapy IMMUNOSPARKLE BIOSCIENCE LLC (US) 2020-08-11 US claimed
EP-3111800-B1 DEVICE FOR IDENTIFYING ORAL CONDITIONS COLGATE PALMOLIVE CO (US) 2018-11-21 EP claimed
CN-104970898-B For identifying the device of oral conditions 高露洁-棕榄公司 2018-05-29 CN claimed
US-9700395-B2 Device for identifying oral conditions COLGATE-PALMOLIVE COMPANY (US) 2017-07-11 US claimed
EP-3111800-A1 DEVICE FOR IDENTIFYING ORAL CONDITIONS Colgate-Palmolive Company (US) 2017-01-04 EP claimed
CN-104970898-A DEVICE FOR IDENTIFYING ORAL CONDITIONS COLGATE PALMOLIVE CO 2015-10-14 CN claimed
US-20150072301-A1 DEVICE FOR IDENTIFYING ORAL CONDITIONS COLGATE PALMOLIVE CO (US) 2015-03-12 US claimed
US-20120322023-A1 DEVICE FOR IDENTIFYING ORAL CONDITIONS COLGATE-PALMOLIVE COMPANY (US) 2012-12-20 US claimed
CN-102655788-A Device for identifying oral conditions COLGATE PALMOLIVE CO 2012-09-05 CN claimed
EP-0845732-A2 Method for assessing oxidative stress and its control in humans Nikken Foods Company Limited (JP) 1998-06-03 EP claimed
US-12622640-B2 Oral data collecting device for diagnosis or prognosis Emanate Biomedical, Inc. (US) 2026-05-12 US disclosed
US-20260071179-A1 PRODUCTION METHOD OF NERVE CELLS DAMAGED BY OXIDATIVE STRESS AND APPLICATIONS THEREOF FUJIFILM CORPORATION (JP) 2026-03-12 US disclosed
EP-4682249-A1 METHOD FOR PRODUCING NERVE CELLS DAMAGED BY OXIDATION STRESS AND APPLICATION THEREOF FUJIFILM Corporation (JP) 2026-01-21 EP disclosed
WO-2024190850-A1 METHOD FOR PRODUCING NERVE CELLS DAMAGED BY OXIDATION STRESS AND APPLICATION THEREOF 富士フイルム株式会社 2024-09-19 WO disclosed
US-6133306-A Methods of inhibiting neurodegerative diseases THE GENERAL HOSPITAL CORPORATION (US) 2000-10-17 US disclosed
US-5950634-A PREPARING A CHART FOR ASSESSING OXIDATIVE STRESS WHEREIN NUMERICAL FIGURE REPRESENTING THE DEGREE OF EXCESS OR DEFICIENCY OF AN INDICATOR SUBSTANCE INDICATING OXIDATIVE STRESS IN HUMANS NIKKEN FOODS CO., LTD. (JP) 1999-09-14 US disclosed
US-5849782-A Methods of inhibiting neurodegenerative diseases THE GENERAL HOSPITAL CORPORATION (US) 1998-12-15 US disclosed
EP-0845732-A2 Method for assessing oxidative stress and its control in humans Nikken Foods Company Limited (JP) 1998-06-03 EP disclosed
WO-1996021445-A1 METHODS OF INHIBITING NEURODEGENERATIVE DISEASES THE GENERAL HOSPITAL CORPORATION (US) 1996-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10736913-B1 Use of inosine for cancer immunotherapy CD47, ICOS, HAVCR2 POLB 4423/4885P2RY2 574/4885P2RY4 1457/4885
US-12622640-B2 Oral data collecting device for diagnosis or prognosis TAS2R30, TAS2R39, TAS2R46 POLB 3435/4885P2RY2 1064/4885P2RY4 1543/4885
US-20260071179-A1 PRODUCTION METHOD OF NERVE CELLS DAMAGED BY OXIDATIVE STRESS AND APPLICATIONS THEREOF AIFM2, AIFM1, FECH POLB 1638/4885P2RY2 1305/4885P2RY4 1064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.